


Effect of Fingolimod on Diffuse Brain Tissue Damage in Relapsing-Remitting Multiple Sclerosis Patients

Nicola De Stefano, Davorka Tomic, Ernst-Wilhelm Radue, Till Sprenger, Daniela Piani Meier, Dieter Häring, Maria Pia Sormani



PII: S2211-0348(16)30040-2  
DOI: <http://dx.doi.org/10.1016/j.msard.2016.03.017>  
Reference: MSARD382

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 1 October 2015  
Revised date: 23 March 2016  
Accepted date: 29 March 2016

Cite this article as: Nicola De Stefano, Davorka Tomic, Ernst-Wilhelm Radue, Till Sprenger, Daniela Piani Meier, Dieter Häring and Maria Pia Sormani, Effect of Fingolimod on Diffuse Brain Tissue Damage in Relapsing-Remitting Multiple Sclerosis Patients, *Multiple Sclerosis and Related Disorders* <http://dx.doi.org/10.1016/j.msard.2016.03.017>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Effect of Fingolimod on Diffuse Brain Tissue Damage in Relapsing-Remitting Multiple Sclerosis Patients

Nicola De Stefano<sup>a\*</sup>, Davorka Tomic<sup>b</sup>, Ernst-Wilhelm Radue<sup>c</sup>, Till Sprenger<sup>d</sup>, Daniela Piani Meier<sup>b</sup>, Dieter Häring<sup>b</sup>, Maria Pia Sormani<sup>e</sup>

<sup>a</sup>Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.

<sup>b</sup>Novartis Pharma AG, Basel, Switzerland.

<sup>c</sup>Medical Image Analysis Center (MIAC), University Hospital, Basel, Switzerland.

<sup>d</sup>Department of Neurology, DKD Helios Klinik Wiesbaden, Germany.

<sup>e</sup>University of Genoa, Genoa, Italy

douglas.arnold@mcgill.ca)

bnvsinger@earthlink.net)

destefano@unisi.it

\*Correspondence to: Nicola De Stefano, MD PhD Dept. of Medicine, Surgery & Neuroscience, University of Siena, Viale Bracci 2, 53100 Siena, Italy.

## Abstract

### Background

Multiple sclerosis (MS) affects all areas of the brain resulting in both focal and diffuse damage. In Phase 3 clinical trials, fingolimod showed significant reductions in both focal lesions and rate of brain volume loss (BVL) in patients with relapsing-remitting MS.

### Objective

Download English Version:

<https://daneshyari.com/en/article/5912165>

Download Persian Version:

<https://daneshyari.com/article/5912165>

[Daneshyari.com](https://daneshyari.com)